

## Half year update on the DBV Technologies liquidity agreement

**Bagneux, France, July 1, 2014** – Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on June 30th, 2013:

9 018 DBV TECHNOLOGIES' shares  
478,300.41€

As a reminder, during the last half year liquidity agreement on December 31th, 2013, the following assets appeared on the liquidity account:

- 5 253 DBV TECHNOLOGIES' shares  
263,429.63€

### About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: [www.dbv-technologies.com](http://www.dbv-technologies.com)

CAUTION: Viaskin® is not approved for sale in the USA.

Viaskin® and EPIT™ are registered trademarks of DBV Technologies, SA

### DBV Technologies Contacts

#### David Schilansky

Chief Financial Officer

Tel. : +33(0)1 55 42 78 75

[david.schilansky@dbv-technologies.com](mailto:david.schilansky@dbv-technologies.com)

#### Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447


[susanna.mesa@dbv-technologies.com](mailto:susanna.mesa@dbv-technologies.com)

#### Nathalie Donne

Director Business Development & Corporate Communication

Tel. : +33(0)1 55 42 78 72

[nathalie.donne@dbv-technologies.com](mailto:nathalie.donne@dbv-technologies.com)



**DBV IR and Media Contacts**

**Todd James**

U.S. Investor Relations  
The Trout Group  
Tel. : +1 646-378-2926  
[tjames@troutgroup.com](mailto:tjames@troutgroup.com)

**BMC Communications**

Media Relations  
Brad Miles  
Tel. : +1 646-513-3125  
[brad@bmccommunications.com](mailto:brad@bmccommunications.com)